What’s Atossa Genetics Inc (NASDAQ:ATOS) Upside After This Short Interest Increase?

October 2, 2018 - By Richard Conner

Atossa Genetics Inc. (NASDAQ:ATOS) Logo

The stock of Atossa Genetics Inc (NASDAQ:ATOS) registered an increase of 6.66% in short interest. ATOS’s total short interest was 333,000 shares in October as published by FINRA. Its up 6.66% from 312,200 shares, reported previously. With 213,200 shares average volume, it will take short sellers 2 days to cover their ATOS’s short positions. The short interest to Atossa Genetics Inc’s float is 7.08%.

The stock decreased 3.05% or $0.05 during the last trading session, reaching $1.59. About 97,639 shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 80.56% since October 2, 2017 and is downtrending. It has underperformed by 96.18% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $8.75 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

More notable recent Atossa Genetics Inc. (NASDAQ:ATOS) news were published by: Globenewswire.com which released: “Report: Developing Opportunities within Crocs, NetApp, Gannett Co., Atossa Genetics, Omega Flex, and Lithia Motors …” on September 25, 2018, also Nasdaq.com with their article: “Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical …” published on September 12, 2018, Benzinga.com published: “The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares” on September 18, 2018. More interesting news about Atossa Genetics Inc. (NASDAQ:ATOS) were released by: Benzinga.com and their article: “The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration …” published on September 13, 2018 as well as Nasdaq.com‘s news article titled: “Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen” with publication date: September 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: